Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) is now available.
Shanghai Fosun Pharmaceutical has established a Remuneration and Appraisal Committee under its board of directors to enhance its appraisal and remuneration management system for directors and senior management. This committee is responsible for setting appraisal standards, formulating remuneration policies, and making recommendations to the board, aiming to improve corporate governance and align management incentives with company performance. The committee’s establishment is expected to strengthen Fosun Pharma’s governance structure and potentially improve its competitive positioning by ensuring transparent and fair remuneration practices.
The most recent analyst rating on (HK:2196) stock is a Hold with a HK$17.20 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock limited company incorporated in China, operating in the pharmaceutical industry. The company focuses on the development, manufacture, and sale of pharmaceutical products, medical devices, and healthcare services, with a significant presence in both domestic and international markets.
Average Trading Volume: 7,025,116
Technical Sentiment Signal: Buy
Current Market Cap: HK$65.06B
See more insights into 2196 stock on TipRanks’ Stock Analysis page.